Vitrectomy for the management of recurrent retinal detachments

Current Opinion in Ophthalmology

Volumn 8, Issue 3, 1997, Pages 44-49

  Holekamp, Nancy M ^a   Grand, M Gilbert ^a  

^a BARNES RETINA INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PRIORITY JOURNAL; RECURRENT DISEASE; RETINA DETACHMENT; REVIEW; VITRECTOMY; VITREORETINOPATHY;

ANIMALS; FLUOROCARBONS; HUMANS; INTRAOPERATIVE PERIOD; POSTOPERATIVE COMPLICATIONS; RECURRENCE; RETINAL DETACHMENT; SILICONE OILS; TREATMENT OUTCOME; VITRECTOMY;

EID: 0030814324     PISSN: 10408738     EISSN: None     Source Type: Journal    
DOI: 10.1097/00055735-199706000-00008     Document Type: Review

References (30)

1. Escoffery RF, Olk RJ, Grand MG, Boniuk I: Vitrectomy without scleral buckling for primary rhegmatogenous retinal detachment. Am J Ophthalmol 1985, 99:275-281.
2. Chignell AH, Fison LG, Davies EWG: Failure in retinal detachment surgery. Br J Ophthalmol 1973, 57:525-530.
3. Lincoff H, Kreissig I: Extraocular repeat surgery of retinal detachment: • a minimal approach. Ophthalmology 1996, 103:1585-1592. The authors review 1252 cases of scleral buckle procedures, analyzing the cause for primary failure. They also analyze the outcome after repeat surgery with a segmental or encircling buckle. They contend that after failed buckle surgery, the second procedure need not be gas injection or a vitrectomy. The majority of cases can be successfully managed with a segmentai explant.
4. Friedman ES, D'Amico DJ: Vitrectomy alone for the management of • uncomplicated recurrent retinal detachments. Retina 1995, 15:469-474. The authors report their experience with vitrectomy alone for the management of uncomplicated recurrent retinal detachments. In their series of nine eyes, the overall anatomic success rate was 89%.
5. The Retinal Society Terminology Committee: The classification of retinal detachment with proliferative vitreoretinopathy. Ophthalmology 1983, 90:121-125.
6. Cowley M, Conway BP, Campochiaro P, Kaiser PH, Gaskin H: Clinical risk factors for proliferative vitreoretinopathy. Arch Ophthalmol 1989, 107:1147-1151.
7. The Silicone Study Group: Vitrectomy with silicone oil or sulfur hexafluoride gas in eyes with severe proliferative vitreoretinopathy: results of a randomized clinical trial. Silicone Study report I. Arch Ophthalmol 1992, 110:770-779.
8. The Silicone Study Group: Vitrectomy with silicone oil or perfluoropropane gas in eyes with severe proliferative vitreoretinopathy: results of a randomized clinical trial. Silicone Study report II. Arch Ophthalmol 1992, 110:780-792.
9. McCuen BW, Azen SP, Stern W, Lai MY, Lean JS, Linton KLP, Ryan SJ, The Silicone Study Group: Vitrectomy with silicone oil or perfluoropropane gas in eyes with severe proliferative vitreoretinopathy: Silicone Study report III. Retina 1993, 13:279-284.
10. Blumenkranz MS, Azen SP, Aaberg TM, Boone DC, Lewis H, Radtke N, Ryan SJ, The Silicone Study Group: Relaxing retinotomy with silicone oil or long-acting gas in eyes with severe proliferative vitreoretinopathy: Silicone Study report V. Am J Ophthalmol 1993, 116:557-564.
11. Barr CC, Lai MY, Lean JS, Linton KLP, Trese M, Abrams G, Ryan SJ, Azen SP, The Silicone Study Group: Postoperative intraocular pressure abnormalities in the Silicone Study: Silicone Study Report IV. Ophthalmology 1993, 100:1629-1635.
12. Hutton WL, Azen SP, Blumenkranz MS, Lai MY, McCuen BW, Han DP, Flynn HW, Ramsey RC, Ryan SJ, The Silicone Study Group: The effects of silicone oil removal: Silicone Study Report VI. Arch Ophthalmol 1994, 112:778-785.
13. Abrams GW, Azen SP, Barr CC, Lai MY, Hutton WL, Trese MT, Irvine A, Ryan SJ, The Silicone Study Group: The incidence of corneal abnormalities in the silicone study: Silicone Study Report VII. Arch Ophthalmol 1995, 113:764-769.
14. Lean J, Azen SP, Lopez PF, Kian D, Lai MY, McCuen B, The Silicone • Study Group: The prognostic utility of the silicone study classification system: Silicone Study Report IX. Arch Ophthalmol 1996, 114:286-292. Using data collected from the Silicone Oil Study, the authors demonstrate that joint knowledge of the location of PVR and the tightness of funnel for a retina with 9 to 12 clock hours involved by fixed folds has prognostic utility for eyes with anterior and posterior PVR.
15. Diddie KR, Azen SP, Freeman HM, Boone DC, Aaberg TM, Lewis H, • Radtke ND, Ryan SJ, The Silicone Study Group: Anterior proliferative vitreoretinopathy in the Silicone Study: Silicone Study Report X. Ophthalmology 1996, 103:1092-1099. Using data collected by the Silicone Oil Study, the authors demonstrate that classifying anterior PVR is prognostic of anatomic and visual outcome. Eyes with anterior PVR and clinically significant posterior PVR had a better visual prognosis if silicone oil was used.
16. Eaton AM, Jaffe GJ, McCuen BW, Mincey GJ: Condensation on the pos•• terior surface of silicone intraocular lenses during fluid/air exchange. Ophthalmology 1995, 102:733-736. Posterior chamber foldable silicone IOLs placed in conjunction with small-incision cataract surgery have been found to develop condensation during fluid-air exchanges during pars plana vitrectomy.
17. Bartz-Schmidt KU, Kirchhof B, Heimann K: Condensation on IOLs during fluid/air exchange [letter]. Ophthalmology 1996, 103:199.
18. Apple JD, Federman JL, Krolicki TJ, Sims JCR, Kent DG, Hamburger HA, • Smiddy WE, Cox MS, Hassan TS, Comptom SM, Thomas SG: Irreversible silicone adhesion to silicone intraocular lenses: a clinicopathologic analysis. Ophthalmology 1996, 103:1555-1562. This report documents adherence of silicone oil used in vitreoretinal surgery to previously implanted silicone IOLs. This complication often necessitates explantation of the lens. Implantation of silicone IOLs should be reconsidered in patients with severe vitreoretinal disease.
19. Stolba U, Binder S, Velikay M, Wedrich A: Intraocular silicone lenses in silicone oil: an experimental study. Graefes Arch Clinic Exp Ophthalmol 1996, 234:55-57.
20. Madreperla SA, McCuen BW: Inferior peripheral iridectomy in patients receiving silicone oil: rates of postoperative closure and effect on oil position. Retina 1995, 15:87-90.
21. MacCumber MW, McCuen BW, Toth CA, Ferrone PJ, Jaffe GJ: Tissue • plasminogen activator for preserving inferior peripheral iridectomy patency in eyes with silicone oil. Ophthalmology 1996, 103:269-273. The authors review 12 patients who underwent vitrectomy with silicone tamponade and peripheral iridectomy for complicated retinal detachment. The authors demonstrate that intraocular tissue plasminogen activator can be safely used to lyse postoperative fibrin occluding the inferior peripheral iridectomy in these eyes.
22. Peyman GA, Schulman JA, Sullivan B: Perfluorocarbon liquids in oph•• thalmology. Surv Ophthalmol 1995, 39:375-395. The authors present an extensive review of the history of PFCLs and their current use in state-of-the-art vitreoretinal surgery.
23. Bourke RD, Simpson RN, Cooling RJ, Sparrow JR: The stability of perfluoro-N-octane during vitreoretinal procedures. Arch Ophthalmol 1996, 114:537-544.
24. Coll GE, Schang S, Sun J, Wieland MR, Berrocal MH: Perfluorocarbon liquid in the management of retinal detachment with proliferative vitreoretinopathy. Ophthalmology 1995, 102:630-639.
25. Stolba U, Binder S, Velikay M, Datlinger P, Wedrich A: Use of perfluorocarbon liquids in proliferative vitreoretinopathy: results and complications. Br J Ophthalmol 1995, 79:1106-1110.
26. Alster Y, Ben-Nun Y, Loewenstein A, Lazar M: Pupillary block glaucoma due to residual perfluoro-decalin. Ophthalmic Surg Lasers 1996, 27:395-396.
27. Banker AS, Freeman WH, Vander SF, Flores-Aguilar M, Munguia D, The •• Wills Eye Hospital Perflubron Study Group: The use of perflubron as a new temporary vitreous substitute and manipulation agent for vitreoretinal surgery. Retina 1996, 16:285-291. The authors report their experience using perfluorocytlbromide as a new type of PFCL for state-of-the-art vitreoretinal surgery. They suggest it may be useful for long-term intraocular tamponade.
28. Flores-Aguilar M, Munguia D, Loeb E: Intraocular tolerance of perfluorocytlbromide (perflubron). Retina 1995, 15:3-13.
29. Fekrat S, deJuan E Jr, Campochiaro PA: The effect of oral 13-cis-retinoic acid on retinal redetachment after surgical repair in eyes with proliferative vitreoretinopathy. Ophthalmology 1995, 102:412-418.
30. Lean JS, Stern WH, Irvine AR, Azen SP, The Silicone Study Group: Classification of proliferative vitreoretinopathy used in the silicone study. Ophthalmology 1989, 96:765-771.